Julie Irving

Analysis of BCR–ABL1 tyrosine kinase domain mutational spectra in primitive chronic myeloid leukemia cells suggests a unique mutator phenotype

M. Dyer, L. Foroni, G. Gerrard, 2010, Leukemia.

A phase I/II trial of AT9283, a selective inhibitor of aurora kinase in children with relapsed or refractory acute leukemia: challenges to run early phase clinical trials for children with leukemia

G. Acton, A. Boddy, P. Kearns, 2017, Pediatric blood & cancer.